



CODEN [USA]: IAJPBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.1464193>Available online at: <http://www.iajps.com>

Research Article

**ANALYSIS OF INTERACTION OF ANTIMICROBIAL
PEPTIDES AS AN ALTERNATIVE TREATMENT OF
TUBERCULOSIS**¹Dr. Muhammad Wahab Saeed, ²Dr. Sadia Rani, ³Dr. Waleed Manzoor¹Medical Officer at RHC 105/15 L, Khanewal²Women Medical Officer at BHU Mehar Pur, Nankana Sahib³Medical Officer at BHU 442GB Samundri, Faisalabad**Abstract:**

Introduction: Tuberculosis (TB) is still one of the most deadly communicable diseases worldwide. In 2013, an estimated 9 million people developed TB and 1.5 million people died from TB. The global trend is a decrease of incidence, prevalence, and mortality. **Objectives of the study:** The basic aim of the study is to analyze the interaction of antimicrobial peptides as an alternative treatment of tuberculosis. **Methodology of the study:** This cross sectional study was conducted at hospitals of Khanewal during July 2018. The patients of both genders were selected for this study. Those patients who suffered from TB from last one year was included in this study. In this analyzes we compare the different drugs of TB which are available in the market as compared to antimicrobial peptides. **Results:** In general the three methods led to the same results. Linde et al. and other groups assayed the antimycobacterial activity by the BACTEC radio-metric method, which detected growth of mycobacteria by measurement of CO₂ released as a consequence of bacterial catabolism. **Conclusion:** It is concluded that Many AMPs have good or moderate activities against mycobacteria; however, in general the activities are lower as compared to the activities found against other Gram-negative or Gram-positive bacteria.

Corresponding author:

Dr. Muhammad Wahab Saeed,
Medical Officer at RHC 105/15 L,
Khanewal

QR code



Please cite this article in press Muhammad Wahab Saeed et al *Analysis of Interaction of Antimicrobial Peptides as an Alternative Treatment of Tuberculosis* ., *Indo Am. J. P. Sci*, 2018; 05(10).

INTRODUCTION:

Tuberculosis (TB) is still one of the most deadly communicable diseases worldwide. In 2013, an estimated 9 million people developed TB and 1.5 million people died from TB [1]. The global trend is a decrease of incidence, prevalence, and mortality. However, with the emergence of multi-drug resistant (MDR) and extensively drug resistant (XDR) *Mycobacterium tuberculosis (Mtb)* strains, new classes of anti-mycobacterial agents are urgently needed. MDR strains are resistant at least against isoniazid (INH) and rifampicin (RIF) and XDR strains are resistant against INH, RIF, fluoroquinolone, and one of amikacin, kanamycin, or capreomycin [2].

Mycobacterium tuberculosis, the causative agent of TB, was discovered by Robert Koch at the end of the nineteenth century. This infectious killer agent currently is one of the most common diseases, infecting approximately one-third of the world's population. According to the WHO survey, it is estimated that there were 8.6 million people infected with TB in 2012. In addition, there are an estimated 450000 MDR-TB cases and 170000 fatalities occur as a result [3]. The development of new cases, adverse events in response to anti-TB drugs, comorbidity with HIV and the lack of an effective vaccine pose great problems in the search for new anti-TB drugs.

Due to continuous failure of antibiotics against drug resistant bacteria, pharmaceutical industries are looking for alternative strategy. One of the possible alternatives to antibiotics (traditional drug mainly based on small molecules) is peptide based therapeutics [4]. A significant and vast majority of peptides from plant, bacteria and fungus sources proven to have anti-microbial action and these can be used as a supplement or alternate for conventional antibiotics. In last few decades, researchers have screened several peptides effective against *Mycobacterium*, which has been used for TB treatment in different therapeutic strategy like as single anti-TB agents, in combination with conventional drugs and synergistic effect with traditional antibiotic therapy [5].

Objectives of the study

The basic aim of the study is to analyze the interaction of antimicrobial peptides as an alternative treatment of tuberculosis.

METHODOLOGY OF THE STUDY:

This cross sectional study was conducted at hospitals of Khanewal during July 2018. The patients of both genders were selected for this study. Those patients who suffered from TB from last one year was included in this study. In this analyzes we compare the different drugs of TB which are available in the market as compared to antimicrobial peptides. No novel drugs have been on the market against TB in the past 40 years except the novel anti-TB drug bedaquiline, which was approved in 2012. A reasonable approach to find new therapeutics against the high number of MDR and XDR strains is to find molecules having a different killing mechanism. It has been shown that naturally occurring antimicrobial peptides (AMPs), also called host defense peptides (HDPs), are an important part of the innate immunity of humans.

Three potential ways of using AMPs in TB infections are discussed in literature: (i) stimulation of the endogenous production of AMPs for direct bacterial killing, (ii) administration of AMPs also for direct killing, and (iii) modulation of the innate immune response by endogenous and externally applied AMPs. Two TB conditions have to be distinguished: the acute and the latent phase. In the latent phase persons do not have any symptoms.

Presence of AMPs in the lung

In the last 20 years, most of the AMPs which are expressed in the lung are tested against mycobacteria. Furthermore, many other AMPs including synthetic compounds were investigated. Most of the authors determined the activity against the *Mtb* H37Rv strain, which helps to compare the results. On the other hand, the assays as well as the conditions used are quite diverse. Miyakawa et al. compared three different techniques for the determination of the activity of the AMPs: CFU counting, radiometric method, and radial diffusion assay.

RESULTS:

In general the three methods led to the same results. Linde et al. and other groups assayed the antimycobacterial activity by the BACTEC radiometric method, which detected growth of mycobacteria by measurement of CO₂ released as a consequence of bacterial catabolism. Other groups use resazurin as an indicator of residual bacterial viability or imaged the growth in 96 well plates using light microscopy

Table 01: Activities of various AMPs including the mycobacterial strains and conditions used in the respective experiments.

AMP	Bacterial strain	Conditions	Activity
hNP-1, hNP-2, hNP-3	M. avium–M. intracellulare	CFU counting, 37 °C, 1:100 Middlebrook 7H10, 2.5×10^6 or 2.5×10^8 bacteria, AMP conc.	Between 34.2 and 87.2% at 50 µg/ml hNP-1
hNP-1, hNP-2, hNP-3, sNP-1, NP-2, PG-1	Mtb H37Ra and clinical isolates	CFU counting, radiometric method, radial diffusion assay, 37 °C, 1:100 Middlebrook, 5.1×10^5 or 4.5×10^7 bacteria, Incubation time (6 to 48 h), AMP concentration (5 and 50 µg/ml), Incubation time (6 to 48 h), pH (between 2 and 8), different salt concentrations	Between 85.9 and 97.5% at 50 µg/ml after 24 h incubation time
Granulysin	Mtb H37Rv	CFU counting, radial diffusion assay, 37 °C, Middlebrook 7H9 with OADC, 2×10^6 bacteria, Incubation time (72 h), AMP conc. (between 1 and 30 µM), Activity against extra- and intracellular Mtb	Extracellular: 90% at 30 µM Intracellular: Only in presence of perforin
PG-1, hBD-1	Mtb H37Rv (ATCC 27294) and the MDR RM22 strain	CFU counting, Middlebrook 7H9, 1×10^3 bacteria Incubation time (0 and 3 days), AMP conc. (between 4 and 128 µg/ml)	PG-1: 68.4% at 64 µg/ml and 96.7% at 128 µg/ml hBD-1: 49.9% at 128 µg/ml Synergistic effect with isoniazid
PR-39 (hNP-1, PG-1, cecropin P1, LL-37)	Mtb H37Rv ATCC 25618, Mtb E1380/94 and P35/95 (MDR clinical isolates) M. avium ATCC 26518	CFU counting, radiometric assay, 37 °C, Middlebrook 7H12, 1.5×10^6 bacteria, Incubation time (24 h), AMP conc. (50, 100 µg/ml)	PR-39: 60% inhibition at 50 µg/ml against H37Rv and 39 and 49% against E1380/94 and P35/95 Comparable activity of HNP-1 and PG-1, no activity of LL-37 and cecropin P1
hNP1–3, LL-37, lipocalin 2	M. bovis-BCG, Mtb H37Rv	CFU counting, 37 °C, Middlebrook 7H9, 6×10^5 bacteria, Incubation time (168 h and 192 h), effect of iron	Iron dependent activity of lipocalin 2 (5 µg/ml)
NK-lysin, peptides based on NK-lysin and granulysin	Mtb H37Rv	BACTEC radiometric assay, PBS, 7.5×10^5 bacteria Incubation time (8 days), AMP conc. (3, 30 µM)	90% growth inhibition of the peptides at 30 µM, 60% of native NK-lysin
LL-37, mCRAMP, E2, E6, CP26	Mtb H37Rv, MDR strain	Resazurin assay, 37 °C, Middlebrook 7H9 with OADC, Incubation time (5 days), AMP conc. (0.4–12.8 µg/ml)	MIC values between 2 and 10 µg/ml
LL-37	M. marinumNJB0419	CFU counting, Middlebrook 7H9 with OADC, AMP conc. (10 µg/ml)	No activity at 10 µg/ml
LL-37 (L and D enantiomer)	Mtb H37Rv and Mtb Vertulo (MDR)	CFU counting, 37 °C, Middlebrook 7H9, 1×10^6 bacteria/ml, AMP conc. (1, 10, 100 µg/ml)	No activity of the L- and low activity of the D-enantiomer at 100 µg/ml

Lactoferricins are naturally occurring peptides, formed by the cleavage of the highly cationic N1 terminal domain of the iron-binding protein lactoferrin⁶. All peptides showed an antimycobacterial activity with LD50 values between 10 and 40 μ M. The stronger activity was found in the bovine-based peptides. A significant difference in the activity against three different *M. avium* strains could not be found [7].

PR-39, a proline–arginine rich AMP isolated from pig intestine, has activity against drug-susceptible as well as MDR clinical isolates of *Mtb*. At 50 μ g/ml 80% growth inhibition of *Mtb* H37Rv could be achieved. Martineau et al. investigated the role of iron concentration on the activity of lipocalin 2. Lipocalin 2–induced suppression of *Mtb* CFU was greater in iron-depleted broth (10 nM iron) than in iron-replete broth (150 μ M Fe) with values of 60% versus 45%, respectively [8].

Azurophil granule protein (AZP) is active against *M. smegmatis* and *M. bovis* BCG [73]. Jena et al. investigated this mixture of molecules and identified elastase and lysozyme to be important for mycobacterial killing⁹. Elastase reduced *M. smegmatis* growth by approximately 60% and lysozyme by approximately 75% at 10 μ g/ml after 6 h.

Two very promising new antimycobacterial peptides were found in screens of extracts from uncultured species. From *Lentzea kentuckyensis* the posttranslationally modified 16 amino acid long peptide lassomycin was purified¹⁰. In lassomycin the N-terminal residues form an eight-residue ring through formation of an amide bond between the N-terminal amine and the side chain carboxyl group of Asp8. In contrast, no activity was found against other Gram-positive and Gram-negative bacteria. A second AMP from uncultured species is teixobactin. The activity against *Mtb*H37Rv is very high with an MIC of 0.125 μ g/ml. Another mechanism is discussed for teixobactin. In case of *S. aureus* teixobactin binds to lipid II, which is the precursor of peptidoglycan, leading to an inhibition of cell wall synthesis [11].

CONCLUSION:

It is concluded that Many AMPs have good or moderate activities against mycobacteria; however, in general the activities are lower as compared to the activities found against other Gram-negative or Gram-positive bacteria. One big advantage of AMPs

is that the active ones showed almost same activities against *Mtb* strains being sensitive against conventional antibiotics and also against MDR and XDR strains.

REFERENCES:

1. Chongsiriwatana N. P., et al. 2011. Short alkylated peptoid mimics of antimicrobial lipopeptides. *Antimicrob. Agents Chemother.* **55**:417–420.
2. Fox JL: Antimicrobial peptides stage a comeback. *Nature biotechnology* 2013; 31:379.
3. Hancock RE, Scott MG: The role of antimicrobial peptides in animal defenses. *Proc Nat Acad Sci.* 2000; 97:8856-61.
4. Brown KL, Hancock RE: Cationic host defense (antimicrobial) peptides. *Current opinion in immunology* 2006; 18:24-30.
5. Zeya HI, Spitznagel JK: Cationic proteins of polymorphonuclear leukocyte lysosomes II. Composition, properties, and mechanism of antibacterial action. *Journal of bacteriology* 1966; 91:755-62.
6. Boman HG: Antibacterial peptides: basic facts and emerging concepts. *Journal of internal medicine* 2003; 254:197-215.
7. Zasloff M: Antibiotic peptides as mediators of innate immunity. *Current opinion in immunology* 1992; 4:3-7.
8. Hoskin DW, Ramamoorthy A: Studies on anticancer activities of antimicrobial peptides. *Biochimica et Biophysica Acta (BBA)-Biomembranes* 2008; 1778:357-75.
9. Chung YS, Kocks C: Recognition of pathogenic microbes by the Drosophila phagocytic pattern recognition receptor Eater. *Journal of Biological Chemistry* 2011; 286:26524-32.
10. Alalwani SM, Sierigk J, Herr C, Pinkenburg O, Gallo R, Vogelmeier C, Bals R: The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils. *European journal of immunology* 2010; 40:1118-26.
11. Van der Does AM, Bogaards SJ, Ravensbergen B, Beekhuizen H, van Dissel JT, Nibbering PH: Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. *Antimicrobial agents and chemotherapy* 2010; 54 :811-6.